Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nanrilkefusp alfa

A human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activities. Upon administration, nanrilkefusp alfa activates and increases the levels of natural killer (NK) cells and memory CD8+ T cells. The memory T cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. Nanrilkefusp alfa is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IL-15/IL-15 receptor alpha sushi+ domain fusion protein SO-C101
interleukin-15/interleukin-15 receptor alpha sushi+ domain fusion protein SO-C101
interleukin-15/interleukin-15 receptor alpha sushi+ domain fusion protein SOT101
Code name:RLI 15
RLI-15
RLI15
SO C101
SO-C101
SOC101
SOT 101
SOT-101
SOT101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search